DAPT
Eligibility
Persons may be eligible to participate in this trial if they meet the following criteria.
- 18 years or older
- Undergoing PCI with stent within past 24 hours
- No contraindication to DAPT for 30 mos. after enrollment (stent)
- Voluntarily consents
Persons may be excluded from this trial if they meet the following criteria.
- Pregnant women
- Planned surgery needing to D/C antiplatelet tx in 30 mos.
- Life expectancy less than 3 years
- Currently enrolled in another study
- On Coumadin or similar anticoagulant therapy
- Allergy to Plavix or Effient
- Stented with both DES and BMS during index procudure
- PCI with stent diameter less <2.25mm or >4.0 mm
Complete Title
Dual Antiplatelet Therapy -- DAPT
Purpose
To assess the effectiveness and sefety of 12 versus 30 months of dual antiplatelet therapy in subjects undergoing Percutaneous coronary intervention.
Summary
The DAPT Study is a prospective, mulit-center, randomized, double-blind trial to assess the effectiveness and safety of 12 vs. 30 months of dual antiplatelet therapy (DAPT) in subjects undergoing Percutaneous coronary intervention (PCI) with either drug-eluting stent or bare metal stent placement for treatment of coronary lesions.
Sponsor(s)
- National Institute of Health